A phase 1, double-blind, balanced, randomized, two-treatment, two-arm, single-period, single-dose, parallel, comparative pharmacokinetic and pharmacodynamic study of MP14 solution for injection 150 mg/mL in pre-filled syringe of CinnaGen Co., Iran comparing with Xolair®150 mg solution for injection in pre-filled syringe of Novartis Europharm Limited Vista Building Elm Park, Merrion Road Dublin 4 Ireland in normal, healthy, adult, human subjects under fasting conditions.

SEPIDEH YAZDIANPOUR1 个研究点分布在 1 个国家目标入组 170 人开始时间: 2026年1月20日最近更新: 2026年1月6日

试验速览

阶段: 1 期
状态: 尚未招募
发起方
入组人数: 170
试验地点: 1

研究概览研究设计入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

Participants will undergo a screening procedure comprising clinical examination, recording of electrocardiogram and laboratory investigation of blood

as well as urine which will be valid for 21days from the day of screening. Radiological investigations (chest X-ray) will be repeated, if not done in the

past 6 months or if clinically indicated at the time of screening. Participants must be enrolled in the study only after providing written informed consent.

Selection of Participants for the study will be done based on assessment against the inclusion and exclusion criteria.

研究设计

研究类型: Interventional
分配方式: Randomized
盲法: Participant and Investigator Blinded

入排标准

年龄范围: 18.00 Year(s) 至 45.00 Year(s)（—）
性别: All

入选标准

•Healthy adult human subjects 18 to 45 years of age both inclusive and weight 50 and 90 kg BMI 18.5 to 30.0 kg per m² including both.
•Acceptable findings during registration and screening including medical history physical examination laboratory evaluations 12 lead ECG and chest X Ray posteroanterior view.
•Non smokers and non alcoholic.
•Values within normal ranges for laboratory parameters upon evaluation by the investigator or physician for any of the following tests.
•Subject with a total IgE level of 100 IU per mL.
•Subjects able to communicate effectively.
•Subjects willing to give written informed consent and adhere to all the requirements of this protocol.
•Subject willing to abstain from consumption of caffeine and xanthine-containing drinks and products tea coffee chocolate cola etc.
•energy drinks products containing poppy seeds from 72.00 hours prior to admission until the last post dose blood sample collection in study period.
•Subject willing to abstain from consumption of citrus fruits including grapefruit and grapefruit juice and cranberries including juices fruit drinks etc.
•from 7 days before drug administration until the last post dose blood sample collection in study period.
•Male subjects with female partners of reproductive potential should use effective contraception during the study.
•Subjects with normal results of Clinical Breast Examination.
•Postmenopausal for at least 1 year or Surgically sterile bilateral tubal ligation bilateral oophorectomy or hysterectomy has been performed on the subject or Female of childbearing potential practicing an acceptable method of birth control for the duration of the study and at least two weeks thereafter as judged by the investigators such as condoms foams jellies diaphragm and intrauterine device IUD or abstinence.

排除标准

•Volunteers having known history of contraindication or hypersensitivity e.g. anaphylaxis to Omalizumab or related group of drugs.
•History of significant asthma urticaria or other allergic type reactions after taking aspirin or other NSAIDs. History of aggravated allergy hypersensitivity to excipients in study drugs or intolerance to these components.
•Presence of autoimmune diseases.
•Acute infectious diseases that ended less than 4 weeks before drug administration.
•History of seizures diabetes migraine hypertension cardiovascular pulmonary neurological or psychiatric disease or disorder dermatological endocrine immunological hepatic renal hematopoietic gastrointestinal ongoing infectious diseases, or any other significant abnormality as evidenced by medical history and physical examination or according to the opinion of the physician.
•History of cerebral infarction myocardial infarction and pulmonary embolism.
•History of gastrointestinal GI inflammation bleeding ulceration and perforation of the stomach small intestine or large intestine.
•History or evidence of exfoliative dermatitis Stevens Johnson syndrome SJS toxic epidermal necrolysis TEN Angioedema and Bullous Pemphigoid.
•Any known enzyme inducing or inhibiting drug taken within 14 days before the study.
•Taking any biological drugs within 3 months or anti IgE biological drugs within 12 months before the study.
•Participation in a drug research study within 90 days prior to dosing of this study.
•Blood loss or whole blood donation within 90 days prior to drug administration.
•Consumption of high caffeine more than 5 cups of coffee or tea per day.
•History of addiction to any recreational drug or drug dependence.
•An unusual or abnormal diet, for whatever reason within 48.00 hours prior to admission of study period e.g. fasting due to religious reasons.
•Taking biological drugs within 3 months or anti IgE biological drugs within 12 months before the study.
•History of dehydration from diarrhea vomiting or any other reason within a period of 48.00 hours prior to study admission.
•Positive results for drugs of abuse benzodiazepines cocaine opioids amphetamines cannabinoids and barbiturates in urine during the admission of study period.
•Positive results for alcohol consumption test breath alcohol or urine alcohol during the admission of study period.
•History or presence of any bleeding disorder.
•Difficulty with donating blood.
•Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg. Diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg. Pulse rate less than 70 beats per minute or more than 100 beats per minute.
•Use of any prescription drugs within 14 days or at least 5 half lives of the compound whichever period is longer prior to study admission.
•and Use of herbal medicines and any OTC medications including vitamins within 14 days or at least 5 half lives of the compound whichever period is longer prior to study admission History of alcohol abuse and or dependence within six months of the screening visit or History of drug abuse or use of illegal drugs within 90 days prior to admission of this study.
•Female subjects demonstrating a positive pregnancy screen.
•Female volunteer who is pregnant or currently breast feeding.
•Female volunteer who has used implanted or injected hormonal contraceptives anytime during the 6 months prior to study or used hormonal contraceptives within 14 days before dosing.

研究者

发起方

SEPIDEH YAZDIANPOUR

申办方类型

Pharmaceutical industry-Global

责任方

Principal Investigator

主要研究者

Dr Sowmya Bondalapati MD

Jeevan Scientific Technology Ltd

研究点 (1)

Loading locations...

相似试验

尚未招募

1 期

A study to determine comparative pharmacokinetic study of BE1040V injection 400mg/ 16ml comparing with Avastin 400mg/ 16ml concentrate for solution for infusion of healthy, adult, human participants.

CTRI/2026/01/100906Sepideh Yazdianpour130

尚未招募

不适用

A study to determine food effect of ND 10 (7- Methylxanthine, a caffeine derivative) Extended- Release Tablets 250 mg two tablets together in healthy human participants

CTRI/2025/09/094030Dr AKBAR WAJID28

已完成

不适用

A study to determine bioavailability and safety of ND 10 (7 Methylxanthine a caffeine derivative) Extended Release Tablets 500 mg

CTRI/2024/02/062928Dr AKBAR WAJID14

尚未招募

不适用

To compare the rate and extent of absorption of Dexamethasone 20 mg Tablets

CTRI/2024/09/074200GALENpharma GmbH42

已完成

不适用

A study to determine the absorption and safety of ND 10 (7 Methylxanthine a caffeine derivative) Extended Release Tablets 500 mg

CTRI/2024/02/062927Dr AKBAR WAJID14